NIH3T3 Directs Memory-Fated CTL Programming and Represses High Expression of PD-1 on Antitumor CTLs
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Qin, Yingyu | - |
dc.contributor.author | Lee, Yuna | - |
dc.contributor.author | Seo, Jaeho | - |
dc.contributor.author | Kim, Taehyun | - |
dc.contributor.author | Shin, Jung Hoon | - |
dc.contributor.author | Park, Se-Ho | - |
dc.date.accessioned | 2021-09-01T16:10:37Z | - |
dc.date.available | 2021-09-01T16:10:37Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-04-11 | - |
dc.identifier.issn | 1664-3224 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/66025 | - |
dc.description.abstract | Memory CD8(+) T cells have long been considered a promising population for adoptive cell therapy (ACT) due to their long-term persistence and robust re-stimulatory response. NIH3T3 is an immortalized mouse embryonic fibroblast cell line. We report that NIH3T3-conditioned medium (CM) can augment effector functions of CTLs following antigen priming and confer phenotypic and transcriptional properties of central memory cells. After NIH3T3-CM-educated CTLs were infused into naive mice, they predominantly developed to central memory cells. A large number of NIH3T3-CM-educated CTLs with high functionality persisted and infiltrated to tumor mass. In addition, NIH3T3-CM inhibited CTLs expression of PD-1 in vitro and repressed their high expression of PD-1 in tumor microenvironment after adoptive transfer. Consequently, established tumor models showed that infusion of NIH3T3-CM-educated CTLs dramatically improved CTL mediated-antitumor immunity. Furthermore, NIH3T3-CM also promoted human CD8(+) T cells differentiation into memory cells. These results suggest that NIH3T3-CM-programmed CTLs are good candidates for adoptive transfer in tumor therapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | FRONTIERS MEDIA SA | - |
dc.subject | CD8(+) T-CELLS | - |
dc.subject | CUTTING EDGE | - |
dc.subject | STEM-CELLS | - |
dc.subject | EFFECTOR | - |
dc.subject | FIBROBLASTS | - |
dc.subject | BET | - |
dc.subject | BLIMP-1 | - |
dc.subject | LYMPHOCYTES | - |
dc.subject | ACTIVATION | - |
dc.title | NIH3T3 Directs Memory-Fated CTL Programming and Represses High Expression of PD-1 on Antitumor CTLs | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Se-Ho | - |
dc.identifier.doi | 10.3389/fimmu.2019.00761 | - |
dc.identifier.scopusid | 2-s2.0-85065395370 | - |
dc.identifier.wosid | 000464279300001 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN IMMUNOLOGY, v.10 | - |
dc.relation.isPartOf | FRONTIERS IN IMMUNOLOGY | - |
dc.citation.title | FRONTIERS IN IMMUNOLOGY | - |
dc.citation.volume | 10 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.subject.keywordPlus | CD8(+) T-CELLS | - |
dc.subject.keywordPlus | CUTTING EDGE | - |
dc.subject.keywordPlus | STEM-CELLS | - |
dc.subject.keywordPlus | EFFECTOR | - |
dc.subject.keywordPlus | FIBROBLASTS | - |
dc.subject.keywordPlus | BET | - |
dc.subject.keywordPlus | BLIMP-1 | - |
dc.subject.keywordPlus | LYMPHOCYTES | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordAuthor | NIH3T3-CM | - |
dc.subject.keywordAuthor | cytotoxic T lymphocytes | - |
dc.subject.keywordAuthor | memory precursor | - |
dc.subject.keywordAuthor | memory CD8(+) T cells | - |
dc.subject.keywordAuthor | adoptive cell therapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.